

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sirnaomics Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Poon Hung Fai (“**Dr. Poon**”) has been appointed as executive Director with effect from October 15, 2024.

The biographical details of Dr. Poon are set out as follows:

Dr. Poon, aged 46, has more than 19 years of experience in the biotechnology sector. He founded QuaCell Biotechnology Co., Ltd. (“**QuaCell**”), a company primarily engaged in the research and manufacturing of core materials for biopharmaceutical production, in April 2018 and served as its general manager until April 2024. QuaCell was acquired by Shanghai LePure Biotech Co., Ltd. (“**LePure Biotech**”), a company primarily engaged in the research and development and the production of single-use equipment and consumables, in January 2023, and Dr. Poon currently serves as the chief strategy officer of LePure Biotech since January 2023. Dr. Poon also served as (i) the chief scientific officer of Hisun Pharmaceutical (Hangzhou) Co., Ltd., the then subsidiary and currently an investee company of Zhejiang Hisun Pharmaceutical Co., Ltd. listed on the Shanghai Stock Exchange (stock code: 600267), from June 2017 to November 2017, and as the R&D director of cell culture from September 2012 to June 2017; and (ii) a senior scientist of Sigma-Aldrich Fine Chemicals (currently a subsidiary of Merck KGaA, a science and technology company listed on the Frankfurt Stock Exchange (stock code: MRK)) from December 2007 to August 2012.

Dr. Poon received his bachelor’s degree of science in chemistry from the University of Kentucky in the U.S. in May 2001, and a doctoral degree in biological/analytical chemistry from the same university in December 2005. Dr. Poon also received a master of business administration degree from the University of South Florida in the U.S. in December 2010.

The Board considered and accepted the recommendation from the nomination committee of the Board to the appointment of Dr. Poon as an executive Director, after reviewing his education background, scientific credentials and professional experience.

As at the date of this announcement, Dr. Poon was deemed to be interested in an aggregate of 17,527,696 shares of the Company (the “**Shares**”) and underlying Shares, within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Dr. Poon has entered into a service contract (the “**Service Contract**”) with the Company in relation to his appointment as an executive Director for a term of three years commencing from October 15, 2024, which may be terminated by not less than 3 months’ notice in writing served by either party on the other and is subject to termination provisions therein and provisions on retirement by rotation of Directors as set out in the articles of association of the Company. Pursuant to the Service Contract, Dr. Poon is entitled to remuneration in accordance with the remuneration policies determined by the remuneration committee of the Board from time to time and, as at the date of this announcement, Dr. Poon is entitled to nil annual emolument.

Save as disclosed above, as at the date of this announcement, Dr. Poon confirmed that (i) he has not held any directorship in other public listed companies in Hong Kong or overseas in the past three years; (ii) he does not hold any other position with the Company or any members of the Group; (iii) he does not have any other major appointments and professional qualifications; (iv) he does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company; (v) he does not hold any other interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (vi) save as disclosed above, there is no other matter in relation to the appointment of Dr. Poon that needs to be brought to the attention of the shareholders of the Company and there is no other information relating to Dr. Poon which is required to be disclosed pursuant to any of the requirements of Rule 13.51(2) (h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
Sirnaomics Ltd.
Yang (Patrick) Lu
Chairman and Executive Director

Hong Kong, October 15, 2024

As at the date of this announcement, the Board comprises Dr. Yang Lu (alias Patrick Lu), Dr. Xiaochang Dai and Dr. Poon Hung Fai as executive Directors, Mr. Mincong Huang and Mr. Jiankang Zhang as non-executive Directors, and Dr. Cheung Hoi Yu, Ms. Monin Ung and Ms. Shing Mo Han, Yvonne (alias Mrs. Yvonne Law) as independent non-executive Directors.